Signet raises $10M for oncology programs

By The Science Advisory Board staff writers

October 29, 2021 -- Signet Therapeutics has raised $10 million in a financing round led by 5Y Capital (Morningside Venture), with participation from Yael Capital, Blue Ocean Capital, and existing investors Tiantu Capital and Sky9 Capital.

The money will go toward advancing the company's two oncology programs to clinical trials. In addition, Signet said it plans to expand its platform of disease models to other cancer areas and enable target discovery and pharmacodynamics studies at other pharmaceutical companies on a greater scale.

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter